VCYT Jefferies Global… Presentation

Page 1

Page 2

Page 3

Page 4

© 2025 Veracyte, Inc. All rights reserved. MORE DATA Broad genomic assays + clinical data Veracyte Diagnostics Platform • Broad genomic assays + clinical data • AI assisted data mining • Robust & efficient evidence generation approach • Differentiated market expansion approach

Page 5

Page 6

Page 7

Page 8

Page 9

Page 10

Page 11

Page 12

Page 13

Page 14

Page 15

Page 16

Page 17

Page 18

Page 19

Page 20

Page 21

Page 22

Page 23

Page 24

Page 25

© 2025 Veracyte, Inc. All rights reserved. (Unaudited) (In thousands of dollars) Three Months Ended Sep 30, 2023 Dec 31, 2023 Mar 31, 2024 Jun 30, 2024 Sep 30, 2024 Dec 31, 2024 GAAP Net Income (Loss) $ (29,618) $ (28,293) $ (1,864) $ 5,734 $ 15,155 $ 5,113 GAAP Net Income (Loss) as a % of Revenue (32.9 %) (28.8 %) (1.9 %) 5.0 % 13.1 % 4.3 % Amortization of intangible assets 5,337 4,563 3,653 3,790 3,797 3,609 Depreciation expense 1,985 1,773 1,937 1,948 2,081 2,643 Stock-based compensation expense 7,332 7,607 8,019 9,854 8,747 9,629 Acquisition related expenses (1) (4,581) 2,718 4,502 1,093 75 961 Other expense (income), net (2) (2,620) (3,399) (3,262) (3,052) (3,366) (1,967) Other adjustments (3) 34,900 32,039 1,450 3,046 (853) 7,807 Income tax expense (benefit) (154) (2,179) (44) 1,627 1,693 (1,670) Adjusted EBITDA $ 12,581 $ 14,829 $ 14,391 $ 24,040 $ 27,329 $ 26,125 Adjusted EBITDA as a % of Revenue 14.0 % 15.1 % 14.9 % 21.0 % 23.6 % 22.0 % 1. Includes transaction-related expenses as well as post-combination compensation expenses. For the three months ended December 31, 2024, adjustments consist primarily of transaction related expenses associated with the acquisition of C2i Genomics ($1.0 million). For the three months ended Sep 30, 2024, adjustments consist primarily of transaction related expenses associated with the acquisition of C2i Genomics ($0.1 million). For the three months ended June 30, 2024, adjustments consist primarily of transaction related expenses associated with the acquisition of C2i Genomics ($1.0 million) and adjustments relating to the remeasurement of contingent consideration related to our adoption of a multi-platform IVD strategy ($0.1 million). For the three months ended Mar 31, 2024, adjustments consist primarily of transaction related expenses associated with the acquisition of C2i Genomics. For the three months ended Dec 31, 2023, adjustments consist primarily of transaction related expenses associated with the acquisition of C2i Genomics ($2.6 million) and remeasurement of contingent consideration related to our adoption of a multi-platform IVD strategy ($0.1 million). For the three months ended Sep 30, 2023, adjustments consist primarily of remeasurement of contingent consideration related to our adoption of a multi-platform IVD strategy and post-combination compensation expenses associated with the acquisition of HalioDx. 2. Includes interest income and income related to research tax credits. 3. For the three months ended December 31, 2024, adjustments primarily include the exclusion of unrealized losses associated with foreign exchange impacts on stock-based compensation and intercompany loans ($1.9 million), expense related to Veracyte SAS site investment review ($3.2 million) and expense related to the impairment charge associated with HalioDx ($2.7 million). For the three months ended Sep 30, 2024, adjustments include the exclusion of unrealized gains associated with foreign exchange impacts on stock-based compensation and intercompany loans ($1.1 million) partially offset by expense related to restructuring costs ($0.2 million). For the three months ended June 30, 2024, adjustments primarily include expense related to restructuring costs associated with a reduction in our Biopharmaceutical and Other segment ($2.9 million) and with portfolio prioritization ($0.2 million). For the three months ended Mar 31, 2024, adjustment includes $1.4 million expense related to restructuring costs associated with portfolio prioritization. For the three months ended Dec 31, 2023, adjustment includes $32.0 million expense related to the impairment charge associated with HalioDx. For the three months ended Sep 30, 2023, adjustment includes $34.9 million related to nCounter license impairment related to our adoption of a multi-platform IVD strategy. 4. Some figures rounded for reporting purposes. Summed quarters may differ slightly from year-to-date figures presented due to rounding.

Page 26

© 2025 Veracyte, Inc. All rights reserved. (Unaudited) (In thousands of dollars) Twelve Months Ended Dec 31, 2023 Dec 31, 2024 GAAP Net Income (Loss) $ (74,404) $ 24,138 GAAP Net Income (Loss) as a % of Revenue (20.6 %) 5.4 % Amortization of intangible assets 20,570 14,849 Depreciation expense 6,618 8,610 Stock-based compensation expense 33,489 36,249 Acquisition related expenses (1) 993 6,631 Other expense (income), net (2) (7,922) (11,647) Other adjustments (3) 68,283 11,450 Income tax expense (benefit) (2,208) 1,606 Adjusted EBITDA $ 45,419 $ 91,886 Adjusted EBITDA as a % of Revenue 12.6 % 20.6 % 1. Includes transaction-related expenses as well as post-combination compensation expenses. For the twelve months ended December 31, 2024, adjustments consist primarily of transaction related expenses associated with the acquisition of C2i Genomics. For the twelve months ended December 31, 2023, adjustments consist primarily of remeasurement of contingent consideration related to our adoption of a multi-platform IVD strategy, post-combination compensation expenses associated with the acquisition of HalioDx and transaction related expenses associated with the acquisition of C2i Genomics. 2. Includes interest income and income related to research tax credits. 3. For the twelve months ended December 31, 2024, adjustments primarily include expense related to restructuring costs associated with a reduction in our Biopharmaceutical and Other segment and with portfolio prioritization, expense related to Veracyte SAS site investment review, expense related to the impairment charge associated with HalioDx and the exclusion of unrealized losses associated with foreign exchange impacts on stock-based compensation and intercompany loans. For the twelve months ended December 31, 2023, adjustments primarily include $34.9 million expense related to the impairment charge associated with the nCounter license intangible assets, $32.0 million expense related to the impairment charge associated with HalioDx and $1.3 million related to other impairment charges.

Page 27

Slides